Linagliptin versus placebo followed by glimepiride in type 2 diabetes patients with moderate to severe renal impairment

被引：0
|
作者：
Groop, P. -H. [1 ,2 ]
Laakso, M. [3 ,4 ]
Rosenstock, J. [5 ]
Hehnke, U. [6 ]
Tamminen, I. [7 ]
Patel, S. [8 ]
von Eynatten, M. [6 ]
Woerle, H. -J. [6 ]
机构：
[1] Univ Helsinki, Cent Hosp, Dept Med, Div Nephrol, Helsinki, Finland
[2] Biomed Helsinki, Folkhalsan Inst Genet, Folkhalsan Res Ctr, Helsinki, Finland
[3] Univ Eastern Finland, Dept Med, Kuopio, Finland
[4] Kuopio Univ Hosp, SF-70210 Kuopio, Finland
[5] Med City, Dallas Diabet & Endocrine Ctr, Dallas, TX USA
[6] Boehringer Ingelheim GmbH & Co KG, Ingelheim, Germany
[7] Boehringer Ingelheim GmbH & Co KG, Helsinki, Finland
[8] Boehringer Ingelheim GmbH & Co KG, Bracknell, Berks, England
来源：
DIABETOLOGIA | 2013年 / 56卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
914
引用
收藏
页码：S364 / S365
页数：2
相关论文
共 50 条
  • [1] Linagliptin vs. Placebo Followed by Glimepiride in Type 2 Diabetes Patients With Moderate to Severe Renal Impairment
    Laakso, Markku
    Rosenstock, Julio
    Groop, Per-Henrik
    Hehnke, Uwe
    Tamminen, Ilkka
    Patel, Sanjay
    Von Eynatten, Maximilian
    Woerle, Hans-Juergen
    DIABETES, 2013, 62 : A281 - A282
  • [2] Linagliptin added to sulphonylurea in uncontrolled type 2 diabetes patients with moderate-to-severe renal impairment
    McGill, Janet B.
    Barnett, Anthony H.
    Lewin, Andrew J.
    Patel, Sanjay
    Neubacher, Dietmar
    von Eynatten, Maximilian
    Woerle, Hans-Juergen
    DIABETES & VASCULAR DISEASE RESEARCH, 2014, 11 (01): : 34 - 40
  • [3] Treatment With the Dipeptidyl Peptidase-4 Inhibitor Linagliptin or Placebo Followed by Glimepiride in Patients With Type 2 Diabetes With Moderate to Severe Renal Impairment: A 52-Week, Randomized, Double-Blind Clinical Trial
    Laakso, Markku
    Rosenstock, Julio
    Groop, Per-Henrik
    Barnett, Anthony H.
    Gallwitz, Baptist
    Hehnke, Uwe
    Tamminen, Ilkka
    Patel, Sanjay
    von Eynatten, Maximilian
    Woerle, Hans-Juergen
    DIABETES CARE, 2015, 38 (02) : E15 - E17
  • [4] Safety and Efficacy of Linagliptin in Type 2 Diabetes Patients with Severe Renal Impairment
    Sloan, Lance
    Newman, Jennifer
    Sauce, Christophe
    Von Eynatten, Maximilian
    Patel, Sanjay
    Woerle, Hans J.
    DIABETES, 2011, 60 : A114 - A114
  • [5] The safety and efficacy of Linagliptin in patients with type 2 diabetes with severe renal impairment
    Sloan, L.
    Newman, J.
    Sauce, C.
    von Eynatten, M.
    Patel, S.
    Woerle, H. J.
    Katsadze, V.
    DIABETES & METABOLISM, 2012, 38 : A102 - A103
  • [6] Management of patients with type 2 diabetes and mild/moderate renal impairment: profile of linagliptin
    Gallwitz, Baptist
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2015, 11 : 799 - 805
  • [7] Efficacy and safety of linagliptin as add-on therapy to sulphonylurea (SU) in type 2 diabetes patients with moderate or severe renal impairment (RI)
    von Eynatten, M.
    Barnett, A. H.
    Patel, S.
    Neubacher, D.
    Woerle, H. -J.
    DIABETOLOGIA, 2012, 55 : S350 - S351
  • [8] Effectiveness and long-term safety of linagliptin in patients with type 2 diabetes and severe renal impairment
    Patel, S.
    Weber, S.
    Emser, A.
    von Eynatten, M.
    Woerle, H. -J.
    Gibelin, B.
    Katsadze, V.
    DIABETES & METABOLISM, 2012, 38 : A103 - A103
  • [9] Long-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment
    Newman, J.
    McGill, J. B.
    Patel, S.
    Friedrich, C.
    Sauce, C.
    Woerle, H. -J.
    DIABETOLOGIA, 2011, 54 : S333 - S333
  • [10] Efficacy and Safety of Gemigliptin in Type 2 Diabetes Patients with Moderate to Severe Renal Impairment
    Yoon, Sun Ae
    Han, Byoung Geun
    Kim, Sung Gyun
    Han, Sang Youb
    Jo, Young-Il
    Jeong, Kyung Hwan
    Oh, Kook-Hwan
    Park, Hyoungchun
    Park, Sun-Hee
    Kang, Shin-Wook
    Na, Ki-Ryang
    Kang, Sun Woo
    Kim, Nam-Ho
    Kim, Sung-Ho
    Jang, Younghwan
    Cha, Dae Ryong
    DIABETES, 2016, 65 : A314 - A315
12345